Drugs / Menstrual blood stem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02095444 | Mar 2014 → Jun 2016 | acute lung injury, acute respiratory distress syndrome, multiple organ dysfunction syndrome | S-Evans Biosciences Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Menstrual blood stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02095444 ↗ |
| Known as | human menstrual blood-derived stem cells | “human menstrual blood-derived stem cells are effective in the treatment of infection of H7N9 virus caused acute lung injury.” NCT02095444 ↗ |
| Modality | Cell therapy | “human menstrual blood-derived stem cells” NCT02095444 ↗ |
| Route | Intravenous | “intravenous injection” NCT02095444 ↗ |